search
Back to results

Use of Hair to Diagnose Breast Cancer

Primary Purpose

Breast Neoplasms

Status
Unknown status
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
x-ray diffraction of human hair
Sponsored by
Fermiscan Ltd
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Breast Neoplasms focused on measuring breast cancer, hair, fibre, synchrotron, x-ray diffraction

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult women (aged >20) who are undergoing mammography at the Mater Hospital, Sydney, and
  • Who are willing and able to provide informed consent; and
  • Who have usable scalp and/or pubic hair

Exclusion Criteria:

  • Women who have dyed or permed their scalp hair within the previous 6 weeks and whose pubic hair is unavailable;
  • Women with a history of breast cancer ever or other cancers (excluding non-melanoma skin cancer and CIN [cervical intra-epithelial neoplasia]) within 5 years.

Sites / Locations

  • The Mater HospitalRecruiting

Outcomes

Primary Outcome Measures

The primary outcome is the determination of the accuracy (sensitivity and specificity) of the x-ray diffraction test for breast cancer using hair. Sensitivity is defined as the proportion of all positive Fermiscan tests that are true positives.

Secondary Outcome Measures

The prevalence of a positive x-ray diffraction hair test and a negative mammogram, and of a negative hair test and a positive mammogram

Full Information

First Posted
January 7, 2007
Last Updated
January 7, 2007
Sponsor
Fermiscan Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT00419679
Brief Title
Use of Hair to Diagnose Breast Cancer
Official Title
A Prospective Blinded Study to Evaluate and Characterise an Assay for the Diagnosis of Breast Cancer Using Synchrotron-Derived X-Ray Diffraction of Hair Fibres.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2007
Overall Recruitment Status
Unknown status
Study Start Date
December 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Fermiscan Ltd

4. Oversight

5. Study Description

Brief Summary
Study FT3.6k-2006 is a single centre (the Mater Hospital, Sydney), blinded trial of a diagnostic test for breast cancer, with outcomes compared to the gold standard of screening mammogram followed by biopsy where required. This study aims to perform X-ray diffraction analysis of coded hair samples from women with a documented breast health status, to validate the findings of James et al (Nature 398: 33-4, 1999; Int J Cancer 114: 969-72, 2005) who showed that the presence of breast cancer could be detected using synchrotron-derived x-ray diffraction of human hair (scalp or pubic). The aim is also to characterise the sensitivity and specificity of the hair test in detecting breast cancer in a screening setting, and to determine the significance of a positive hair test and a negative mammogram.
Detailed Description
The test has the potential to improve the diagnostic (and consequently therapeutic) paradigm for breast cancer. Women attending a radiology clinic in the Mater Hospital, Sydney, for a mammogram will be invited to participate in the study. A few hairs will be cut from their head or pubic region, put into a coded container and sent to the sponsor for analysis by synchrotron-x-ray diffraction. Although an imperfect standard for a variety of reasons, mammography is the standard screening assay, and confirmation of the pathology of the lesions found by mammography is carried out by biopsy. This will be the standard to which the hair test results will be compared. A negative mammogram will confirm a negative hair test, but a negative mammogram combined with a positive hair diffraction test will need a different approach. In the event of a positive hair test and a negative second read of the mammogram, the patient will be contacted by the referring practitioner. Patients in this category will be offered a breast MRI. A negative breast MRI under these circumstances will be classified as a true negative.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms
Keywords
breast cancer, hair, fibre, synchrotron, x-ray diffraction

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Randomized
Enrollment
3600 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
x-ray diffraction of human hair
Primary Outcome Measure Information:
Title
The primary outcome is the determination of the accuracy (sensitivity and specificity) of the x-ray diffraction test for breast cancer using hair. Sensitivity is defined as the proportion of all positive Fermiscan tests that are true positives.
Secondary Outcome Measure Information:
Title
The prevalence of a positive x-ray diffraction hair test and a negative mammogram, and of a negative hair test and a positive mammogram

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult women (aged >20) who are undergoing mammography at the Mater Hospital, Sydney, and Who are willing and able to provide informed consent; and Who have usable scalp and/or pubic hair Exclusion Criteria: Women who have dyed or permed their scalp hair within the previous 6 weeks and whose pubic hair is unavailable; Women with a history of breast cancer ever or other cancers (excluding non-melanoma skin cancer and CIN [cervical intra-epithelial neoplasia]) within 5 years.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter French, BSc, MSc, PhD
Phone
+61292454460
Email
pfrench@fermiscan.com.au
First Name & Middle Initial & Last Name or Official Title & Degree
Gary Corino, BSc
Phone
+61292454460
Email
gcorino@fermiscan.com.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Phillip Yuile, MBBS (Hons), FRNZCR
Organizational Affiliation
The Mater Hospital, Sydney
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Mater Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Phillip Yuile, MBBS (Hons), FRNZCR
Phone
+61299292600
Email
yuilep@optushome.com.au

12. IPD Sharing Statement

Citations:
PubMed Identifier
16876335
Citation
James VJ. A place for fiber diffraction in the detection of breast cancer? Cancer Detect Prev. 2006;30(3):233-8. doi: 10.1016/j.cdp.2006.04.001. Epub 2006 Jul 28.
Results Reference
background
PubMed Identifier
15645416
Citation
James V, Corino G, Robertson T, Dutton N, Halas D, Boyd A, Bentel J, Papadimitriou J. Early diagnosis of breast cancer by hair diffraction. Int J Cancer. 2005 May 10;114(6):969-72. doi: 10.1002/ijc.20824.
Results Reference
background
PubMed Identifier
12529353
Citation
James V. False-positive results in studies of changes in fiber diffraction of hair from patients with breast cancer may not be false. J Natl Cancer Inst. 2003 Jan 15;95(2):170-1. doi: 10.1093/jnci/95.2.170. No abstract available. Erratum In: J Natl Cancer Inst. 2003 Feb 19;95(4):334.
Results Reference
background
PubMed Identifier
11390537
Citation
Meyer P, James VJ. Experimental confirmation of a distinctive diffraction pattern in hair from women with breast cancer. J Natl Cancer Inst. 2001 Jun 6;93(11):873-5. doi: 10.1093/jnci/93.11.873. No abstract available.
Results Reference
background
PubMed Identifier
10078527
Citation
James V, Kearsley J, Irving T, Amemiya Y, Cookson D. Using hair to screen for breast cancer. Nature. 1999 Mar 4;398(6722):33-4. doi: 10.1038/17949. No abstract available.
Results Reference
background

Learn more about this trial

Use of Hair to Diagnose Breast Cancer

We'll reach out to this number within 24 hrs